Reports Q1 revenue $107.5M, consensus $109.36M. “Cellebrite (CLBT) delivered strong 23% ARR growth while pairing solid revenue expansion with prudent spending to drive 34% year-over-year growth in adjusted EBITDA and a 22% margin,” stated Thomas E. Hogan, Cellebrite’s interim CEO. “The strength of our total performance was a byproduct of our global diversification and the range of our solutions across federal, state and local, defense, intelligence and private sectors.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite price target lowered to $25 from $29 at JPMorgan
- Cellebrite announces Spring 2025 Release
- 3 Best Stocks to Buy Now, 4/3/2025, According to Top Analysts
- Cellebrite DI: Strong Long-Term Growth Potential Amid Market Challenges
- Cellebrite’s Strong Platform Appeal and Strategic Focus Justify Buy Rating Amid Policy Stability